title: Factor XI as a target for antithrombotic therapy.
abstract: Anticoagulants currently used in clinical practice to treat thromboembolic disorders are effective but increase the risk of severe bleeding because they target proteins that are essential for normal coagulation (hemostasis). Drugs with better safety profiles are required for prevention and treatment of thromboembolic disease. Coagulation factor XIa has emerged as a novel target for safer anticoagulant therapy because of its role in thrombosis and its relatively small contribution to hemostasis.
authors.affiliation: Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA.
authors.forename: Charles E
authors.initials: CE
authors.lastname: Bane
authors.affiliation: Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA. Electronic address: dave.gailani@vanderbilt.edu.
authors.forename: David
authors.initials: D
authors.lastname: Gailani
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D015195:Drug Design; D005172:Factor XI / Q000037:antagonists & inhibitors*; D015945:Factor XIa / Q000037:antagonists & inhibitors; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D013923:Thromboembolism / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D005172:Factor XI; D015945:Factor XIa